99mTc-MAG3, a new renal imaging agent: preliminary results in patients.
99mTc-MAG3, a new renal imaging agent: preliminary results in patients.
复制标题
99mTc-MAG3，一种新型肾脏显像剂：患者的初步结果。
DOI：
10.1007/bf00620476
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Alazraki,N
中科院分区：
文献类型：
--
作者：
TaylorJr,A;Eshima,D;Alazraki,N
99 mTc-巯基乙酰基三甘氨酸（MAG_3）是一种新的肾脏放射性药物，在动物和志愿者体内显示其生物学特性与~（131）I-马尿酸盐（OIH）相似。在所有病例中，无论血清肌酐如何，99 mTc-MAG 3图像均优于上级图像。所选的例子说明，包括扫描和肾图曲线在正常志愿者，移植患者肌酐9.8毫克/分升和2.6毫克/分升，和呋塞米研究可疑梗阻患者。我们的初步结果表明，99 mTc-MAG 3在肾功能受损的患者中表现良好，并可能为OIH提供可接受的替代品。已经开发了一种试剂盒配方，不久将进行临床评价。
99mTc-mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical which has been shown to have biological properties similar to131I-hippurate (OIH) in animals and volunteers.99mTc-MAG3has now been compared with131I-orthoiodohippurate (OIH) in a group of patients with varying degrees of renal impairment. In all cases, the99mTc-MAG3images were superior regardless of serum creatinine. Selected examples are illustrated including scans and renogram curves in a normal volunteer, transplant patients with creatinines of 9.8 mg/dl and 2.6 mg/dl respectively, and a furosemide study in a patient with questionable obstruction. Our preliminary results suggest that99mTc-MAG3performs well in patients with impaired renal function and may well provide an acceptable replacement for OIH. A kit formulation has been developed and will soon be undergoing clinical evaluation.